Leor Perl1, Hila Lerman-Shivek2, Eldad Rechavia1, Muthiah Vaduganathan3, Dorit Leshem-Lev4, Noa Zemer-Wassercug1, Oshrat Dadush4, Pablo Codner1, Tamir Bental1, Alexander Battler1, Ran Kornowski1, Eli I Lev5. 1. Cardiology Department, Rabin Medical Center, Petah-Tikva, Israel, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 2. Cardiology Department, Rabin Medical Center, Petah-Tikva, Israel, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Clinical Pharmacy Department, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel. 3. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 4. The Felsenstein Medical Research Institute, Rabin Medical Center, Petah-Tikva, Israel. 5. Cardiology Department, Rabin Medical Center, Petah-Tikva, Israel, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: elil@clalit.org.il.
Abstract
OBJECTIVES: The aim of this study was to determine whether response to prasugrel is associated with the proportion of circulating reticulated platelets (RPs) in patients with ST-segment elevation myocardial infarction (STEMI). BACKGROUND: Despite better pharmacodynamic properties and clinical efficacy of prasugrel compared with clopidogrel, antiplatelet responses to prasugrel are not uniform. The mechanism of this variability in response is not clear. RPs, young hyperactive forms, are increased during situations of enhanced platelet turnover. METHODS: Patients with STEMI treated with primary percutaneous intervention (PCI) and prasugrel were tested for platelet reactivity using purinergic receptor P₂Y, G-protein coupled, 12 (P₂Y₁₂) assay and multiple electrode aggregometry (MEA). RP levels were determined using flow cytometry with thiazole orange staining. Tests were performed at 2 to 4 days and 30 days post-PCI. Platelet function was compared by varying levels of RPs, analyzed as continuous (regression analysis) and categorical (tertiles) variables. RESULTS: Sixty-two patients were included (mean age: 57.5 ± 8 years; 21.2% women; 27.7% diabetes). At the early time point, RP levels were strongly correlated with platelet reactivity when evaluated by the P₂Y₁₂ assay (Spearman's correlation coefficient: 0.55 for P₂Y₁₂ reaction units, -0.49 for percent inhibition) and MEA (Spearman's: 0.50). The upper tertile of RPs displayed higher platelet reactivity compared with the middle and lower tertiles, according to P₂Y₁₂ assay and MEA. Similar results with strong correlations between RP and platelet reactivity were noted at 30 days post-PCI. CONCLUSIONS: The proportion of circulating RPs strongly correlates with response to prasugrel in patients with STEMI treated with PCI. High levels of RPs are associated with increased platelet reactivity despite prasugrel treatment.
OBJECTIVES: The aim of this study was to determine whether response to prasugrel is associated with the proportion of circulating reticulated platelets (RPs) in patients with ST-segment elevation myocardial infarction (STEMI). BACKGROUND: Despite better pharmacodynamic properties and clinical efficacy of prasugrel compared with clopidogrel, antiplatelet responses to prasugrel are not uniform. The mechanism of this variability in response is not clear. RPs, young hyperactive forms, are increased during situations of enhanced platelet turnover. METHODS:Patients with STEMI treated with primary percutaneous intervention (PCI) and prasugrel were tested for platelet reactivity using purinergic receptor P₂Y, G-protein coupled, 12 (P₂Y₁₂) assay and multiple electrode aggregometry (MEA). RP levels were determined using flow cytometry with thiazole orange staining. Tests were performed at 2 to 4 days and 30 days post-PCI. Platelet function was compared by varying levels of RPs, analyzed as continuous (regression analysis) and categorical (tertiles) variables. RESULTS: Sixty-two patients were included (mean age: 57.5 ± 8 years; 21.2% women; 27.7% diabetes). At the early time point, RP levels were strongly correlated with platelet reactivity when evaluated by the P₂Y₁₂ assay (Spearman's correlation coefficient: 0.55 for P₂Y₁₂ reaction units, -0.49 for percent inhibition) and MEA (Spearman's: 0.50). The upper tertile of RPs displayed higher platelet reactivity compared with the middle and lower tertiles, according to P₂Y₁₂ assay and MEA. Similar results with strong correlations between RP and platelet reactivity were noted at 30 days post-PCI. CONCLUSIONS: The proportion of circulating RPs strongly correlates with response to prasugrel in patients with STEMI treated with PCI. High levels of RPs are associated with increased platelet reactivity despite prasugrel treatment.
Authors: Adi Lador; Dorit Leshem-Lev; Galia Spectre; Aryeh Abelow; Ran Kornowski; Eli I Lev Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Constance C F M J Baaten; Leo F Veenstra; Rick Wetzels; Johanna P van Geffen; Frauke Swieringa; Susanne M de Witt; Yvonne M C Henskens; Harry Crijns; Sven Nylander; J J J van Giezen; Johan W M Heemskerk; Paola E J van der Meijden Journal: Haematologica Date: 2015-06-25 Impact factor: 9.941
Authors: Thomas Hoefer; Paul C Armstrong; Michaela Finsterbusch; Melissa V Chan; Nicholas S Kirkby; Timothy D Warner Journal: Arterioscler Thromb Vasc Biol Date: 2015-08-13 Impact factor: 8.311